Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUCP8K)

Drug Name
RPK-739 Drug Info
Synonyms KUN-CSF; KUN-GMCSF; Cancer vaccine (KUNrep), Replikun
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Terminated [1]
Cross-matching ID
TTD Drug ID
DMUCP8K

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Granulocyte-macrophage colony-stimulating factor (CSF2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Talimogene Laherparepvec DMKBW5C Melanoma 2C30 Approved [2]
Lenzilumab DMSRIT4 Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 Trial [3]
JX-594 DM5WCV4 Hepatocellular carcinoma 2C12.02 Phase 3 [4]
Mavrilimumab DMMVFRC Rheumatoid arthritis FA20 Phase 2 [5]
Cabiralizumab DMGE058 Pancreatic cancer 2C10 Phase 2 [3]
KB002/003 DM60G5O Rheumatoid arthritis FA20 Phase 2 [6]
GSK3196165 DMEXKF4 Rheumatoid arthritis FA20 Phase 2 [5]
KB-003 DM74KIM Severe asthma CA23 Phase 2 [7]
MT203 DM7I0MT Plaque psoriasis EA90.0 Phase 2 [8]
MORAb-022 DMM7TBO Autoimmune diabetes 5A10 Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Granulocyte-macrophage colony-stimulating factor (CSF2) TTNYZG2 CSF2_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024125)
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361-70.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast.
8 GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev Clin Immunol. 2015 Apr;11(4):457-65.
9 Clinical pipeline report, company report or official report of Morphotek.